You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2) infection and atopic dermatitis
Copyright policy )European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2) infection and atopic dermatitis
Atopic dermatitis (AD) is a complex disease with elevated risk of respiratory comorbidities.1,2 Severely affected patients are often treated with immune-modulating systemic drugs.3,4 On March 11th 2020, the World Health Organization declared the 2019 novel coronavirus severe acute respiratory syndrome (SARS-Cov-2) epidemic to be a pandemic. The number of cases worldwide is increasing exponentially and poses a major health threat, especially for those who are elderly, immuno-compromised, or have comorbidities. This also applies to AD patients on systemic immune-modulating treatment. In these days of uncertainty, reallocation of medical resources, curfew, hoarding, and shutdown of normal social life, patients, caregivers and doctors ask questions regarding the continuation of systemic immune-modulating treatment of AD patients. The ETFAD decided to address some of these questions here.
- University of Sheffield United Kingdom
- Gentofte Hospital Denmark
- University of Amsterdam Netherlands
- University Hospital and Clinics United States
- Universitair Ziekenhuis Brussel Belgium
Microsoft Academic Graph classification: Pediatrics medicine.medical_specialty Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Systemic therapy Pandemic medicine business.industry Task force Atopic dermatitis medicine.disease Comorbidity Pneumonia business Risk assessment
ACM Computing Classification System: ComputingMilieux_MISCELLANEOUS
Male, immunosuppressant, [SDV]Life Sciences [q-bio], Advisory Committees, Pneumonia, Viral, Comorbidity, Dermatology, Severe Acute Respiratory Syndrome, Risk Assessment, systemic therapy, Dermatitis, Atopic, Immunocompromised Host, Humans, Pandemics, atopic dermatitis, SARS-CoV-2, COVID-19, Europe, Treatment Outcome, Infectious Diseases, Practice Guidelines as Topic, Female, Coronavirus Infections, Immunosuppressive Agents
Male, immunosuppressant, [SDV]Life Sciences [q-bio], Advisory Committees, Pneumonia, Viral, Comorbidity, Dermatology, Severe Acute Respiratory Syndrome, Risk Assessment, systemic therapy, Dermatitis, Atopic, Immunocompromised Host, Humans, Pandemics, atopic dermatitis, SARS-CoV-2, COVID-19, Europe, Treatment Outcome, Infectious Diseases, Practice Guidelines as Topic, Female, Coronavirus Infections, Immunosuppressive Agents
Microsoft Academic Graph classification: Pediatrics medicine.medical_specialty Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Systemic therapy Pandemic medicine business.industry Task force Atopic dermatitis medicine.disease Comorbidity Pneumonia business Risk assessment
ACM Computing Classification System: ComputingMilieux_MISCELLANEOUS
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).91 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 1% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1% citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).91 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 1% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!
- University of Sheffield United Kingdom
- Gentofte Hospital Denmark
- University of Amsterdam Netherlands
- University Hospital and Clinics United States
- Universitair Ziekenhuis Brussel Belgium
- Lund University Sweden
- University of Bordeaux France
- Skåne University Hospital Sweden
- University Hospital Bonn Germany
- Erasmus University Rotterdam Netherlands
- University Hospital of Lausanne Switzerland
- Aarhus University Hospital Denmark
- Guy's and St Thomas' NHS Foundation Trust United Kingdom
- Gdańsk Medical University Poland
- University Children’s Hospital Bern Switzerland
- Utrecht University Netherlands
- Ludwig-Maximilians-Universität München Germany
- University Hospital of Bern Switzerland
- Erasmus University Rotterdam Netherlands
- University of Toulouse France
- Hannover Medical School Germany
- University Hospital Schleswig-Holstein Germany
- University of Nantes France
- University of Milan Italy
- University of Bern Switzerland
- Université Paris Diderot France
- Technical University of Munich Germany
Atopic dermatitis (AD) is a complex disease with elevated risk of respiratory comorbidities.1,2 Severely affected patients are often treated with immune-modulating systemic drugs.3,4 On March 11th 2020, the World Health Organization declared the 2019 novel coronavirus severe acute respiratory syndrome (SARS-Cov-2) epidemic to be a pandemic. The number of cases worldwide is increasing exponentially and poses a major health threat, especially for those who are elderly, immuno-compromised, or have comorbidities. This also applies to AD patients on systemic immune-modulating treatment. In these days of uncertainty, reallocation of medical resources, curfew, hoarding, and shutdown of normal social life, patients, caregivers and doctors ask questions regarding the continuation of systemic immune-modulating treatment of AD patients. The ETFAD decided to address some of these questions here.